While novel therapies are able to cure the vast majority of individulas with genotype 1, those with genotype 3 have less robust options. Given that it is prevalent throughout the world and is emerging in young injection drug users, advancing therapeutic options for genotype 3 is one of our next challenges. By presenting a case of a prior nonresponder to interferon-based therapies, current and future management options for genotype 3 will be highlighted.